Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma
Data Availability
Individual participant data underlying the results reported in this publication, along with a data dictionary, will be made available to approved investigators for secondary analyses following the completion of the objectives of the United States Expanded Access Program to COVID-19 convalescent plasma. Limited and de-identified data sets will be deposited into a research data repository and may be shared with investigators under controlled access procedures as approved by the Mayo Clinic Institutional Review Board. A scientific committee will review requests for the conduct of protocols approved or determined to be exempt by an Institutional Review Board. Requestors will be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies.
Subject Area
- Addiction Medicine (372)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2756)
- Dermatology (235)
- Emergency Medicine (414)
- Epidemiology (12404)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4266)
- Geriatric Medicine (396)
- Health Economics (700)
- Health Informatics (2760)
- Health Policy (1020)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4046)
- Nursing (216)
- Nutrition (600)
- Oncology (2132)
- Ophthalmology (606)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1149)
- Primary Care Research (470)
- Public and Global Health (6659)
- Radiology and Imaging (1446)
- Respiratory Medicine (886)
- Rheumatology (421)
- Sports Medicine (353)
- Surgery (465)
- Toxicology (57)
- Transplantation (192)
- Urology (171)